|
|
1.
|
Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31. MedStar authors:
Year: 2013
Citation: - Journal of the National Cancer Institute. 105(23):1782-8, 2013 Dec 4.
Institution: - Washington Cancer Institute
Medline publication type:
- Journal Article
- Randomized Controlled Trial
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't
All authors: - Bandos H, Blackmon NL, Bohn OL, Burandt E, Costantino JP, Fehrenbacher L, Fumagalli D, Gavin PG, Geyer CE Jr, Goldstein LC, Horne ZD, Jeong JH, Kim C, Kim SI, Kim SR, Lee A, Mamounas EP, Paik S, Pogue-Geile KL, Rastogi P, Reilly ML, Remillard MY, Romond EH, Sneige N, Swain SM, Tanaka N, Taniyama Y, Wickerham DL, Wolmark N
|
|
|
2.
|
Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapies. MedStar authors:
Year: 2013
Citation: - Clinical Cancer Research. 19(13):3681-92, 2013 Jul 1.
Institution: - Washington Cancer Institute
Medline publication type:
All authors: - Bais C, Brauer MJ, Chen D, Cheng JH, Chung AS, Clermont AC, Ferrara N, Haley B, Hegde P, James CD, Jubb A, Jurinka SS, Kaminker JS, Koeppen H, Kolumam G, Modrusan Z, Ozawa T, Phillips H, Scherer SJ, Schmidt M, Singh M, Stephan JP, Swain SM, Tam RN, Wu X, Yang SX, Yao J, Yeh RF, Yue P, Zhuang G
|
